Additional information:
Exendin-4 acetate (Exenatide acetate), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.|Product information|CAS Number: 914454-01-6|Molecular Weight: 4917.24|Formula: C212H328N52O80S|Chemical Name: (2R, 4S, 5R, 6S)-5-acetamido-2-[[(2R, 3R, 4S, 5R, 6S)-6-[(2R, 3S, 4R, 5R, 6R)-5-acetamido-6-[[(3S)-3-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S, 3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S, 3R)-2-[[(2S)-2-[[(2S, 3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-4-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-oxobutanoyl]amino]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3, 4, 5-trihydroxyoxan-2-yl]methoxy]-4-hydroxy-6-[(2S, 3R)-2, 3, 4-trihydroxybutyl]oxane-2-carboxylic acid;acetate|Smiles: CC[C@H](C)[C@H](NC(=O)[C@H](CC1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO[C@@]3(C[C@H](O)[C@@H](NC(C)=O)[C@H](C[C@H](O)[C@H](O)CO)O3)C(O)=O)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1NC(C)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O.{{p-Coumaric acid} site|{p-Coumaric acid} Endogenous Metabolite|{p-Coumaric acid} Purity & Documentation|{p-Coumaric acid} In Vivo|{p-Coumaric acid} custom synthesis|{p-Coumaric acid} Cancer} CC(O)=O|InChiKey: YGHQSTMXYLWAJN-ZAVVHXGLSA-N|InChi: InChI=1S/C210H324N52O78S.{{Anti-Mouse CD209b Antibody} medchemexpress|{Anti-Mouse CD209b Antibody} Protocol|{Anti-Mouse CD209b Antibody} References|{Anti-Mouse CD209b Antibody} supplier|{Anti-Mouse CD209b Antibody} Autophagy} C2H4O2/c1-18-101(10)162(200(328)240-123(54-60-159(292)293)185(313)245-130(75-110-81-220-114-41-26-25-40-112(110)114)190(318)242-125(70-97(2)3)187(315)232-116(43-28-30-63-212)180(308)246-131(77-149(278)255-203-166(230-107(16)273)168(297)171(146(94-269)337-203)339-207-170(299)169(298)167(296)147(338-207)95-336-210(208(334)335)80-143(275)165(229-106(15)272)145(340-210)79-142(274)144(276)93-268)176(304)223-83-150(279)221-87-154(283)259-65-32-45-138(259)197(325)252-136(91-266)196(324)250-134(89-264)177(305)225-84-151(280)227-103(12)204(331)261-67-34-47-140(261)206(333)262-68-35-48-141(262)205(332)260-66-33-46-139(260)198(326)249-133(88-263)172(215)300)257-192(320)128(73-108-36-21-19-22-37-108)244-188(316)126(71-98(4)5)241-181(309)117(44-31-64-219-209(216)217)239-199(327)161(100(8)9)256-173(301)102(11)228-178(306)120(51-57-156(286)287)235-183(311)121(52-58-157(288)289)236-184(312)122(53-59-158(290)291)237-186(314)124(61-69-341-17)238-182(310)119(49-55-148(214)277)234-179(307)115(42-27-29-62-211)233-194(322)135(90-265)251-189(317)127(72-99(6)7)243-191(319)132(78-160(294)295)247-195(323)137(92-267)253-202(330)164(105(14)271)258-193(321)129(74-109-38-23-20-24-39-109)248-201(329)163(104(13)270)254-153(282)86-224-175(303)118(50-56-155(284)285)231-152(281)85-222-174(302)113(213)76-111-82-218-96-226-111;1-2(3)4/h19-26,36-41,81-82,96-105,113,115-147,161-171,203,207,220,263-271,274-276,296-299H,18,27-35,42-80,83-95,211-213H2,1-17H3,(H2,214,277)(H2,215,300)(H,218,226)(H,221,279)(H,222,302)(H,223,304)(H,224,303)(H,225,305)(H,227,280)(H,228,306)(H,229,272)(H,230,273)(H,231,281)(H,232,315)(H,233,322)(H,234,307)(H,235,311)(H,236,312)(H,237,314)(H,238,310)(H,239,327)(H,240,328)(H,241,309)(H,242,318)(H,243,319)(H,244,316)(H,245,313)(H,246,308)(H,247,323)(H,248,329)(H,249,326)(H,250,324)(H,251,317)(H,252,325)(H,253,330)(H,254,282)(H,255,278)(H,256,301)(H,257,320)(H,258,321)(H,284,285)(H,286,287)(H,288,289)(H,290,291)(H,292,293)(H,294,295)(H,334,335)(H4,216,217,219);1H3,(H,3,4)/t101-,102-,103-,104+,105+,113-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144+,145-,146+,147+,161-,162-,163-,164-,165+,166+,167-,168+,169-,170+,171+,203+,207-,210+;/m0.PMID:24059181 /s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 66.66 mg/mL (15.70 mM). H2O : 1 mg/mL (0.24 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|In human umbilical vein endothelial cells, Exendin-4 significantly increases NO production, endothelial NO synthase (eNOS) phosphorylation, and GTP cyclohydrolase 1 (GTPCH1) level in a dose-dependent manner. Exendin-4 shows cytotoxic effects to MCF-7 breast cancer cells with IC50 of 5 μM at 48 hour.|In Vivo:|Both low- and high-dose Exendin-4 treatment in ob/ob mice improve serum ALT and reduce serum glucose, and calculated HOMA scores compared with control. Exendin-4-treated ob/ob mice sustain a marked reduction in the net weight gain in the final 4 weeks of the study period. Animals treated with Exendin-4 have more pancreatic acinar inflammation, more pyknotic nuclei and weigh significantly less than control rats. Exendin-4 treatment is associated with lower leptin levels as well as lower HOMA values in rats. Exenatide causes dose-dependent relaxation of rat thoracic aorta, which is evoked via the GLP-1 receptor and is mediated mainly by H2S but also by NO and CO.|Products are for research use only. Not for human use.|